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Abstract 
Background: Characterizing the interactions between the upper and lower airways is important for the 
management of asthma. This study aimed at assessing the specific impact of concomitant rhinitis on asthma-
related quality of life (QOL) and asthma control. 
Methods: A cross-sectional, observational survey was conducted among 1173 patients with asthma (aged 12-45) 
recruited by general practitioners and chest physicians. AR was defined by self-reported rhinitis symptoms and 
previously documented sensi-tization to inhalant allergens. The primary outcomes were (1) asthma control 
assessed by the Asthma Control Questionnaire (ACQ) and (2) asthma-specific QOL evaluated through the Mini 
Asthma Quality of Life Questionnaire (mAQLQ).  
Results: AR was present in 73.9% of the population with asthma and nonallergic rhinitis (NAR) in 13.6%. AR 
and NAR were associated with an increased risk of uncontrolled asthma (i.e. ACQ score > 1.5) with adjusted 
odds ratios (OR) of 2.00 (95% confidence interval [CI]: 1.35-2.97) and 1.77 (95%CI: 1.09-2.89), respectively. 
Multivariate linear regression analysis showed that AR and NAR had a modest, although significant, negative 
impact on the global mAQLQ score (beta coefficient: -0.293, standard error [SE]: 0.063 and beta coefficient: -
0.221, SE: 0.080, P < 0.001, respectively), even after adjustment for the level of asthma control and 
demographic characteristics. 
Conclusion: This survey provides direct evidence that AR and NAR are associated with an incremental adverse 
impact on the disease-specific QOL of patients with asthma and the level of asthma control. Further 
investigations are required to determine whether appropriate treatment of rhinitis would efficiently reduce 
asthma morbidity. 
Keywords : asthma ; quality of life ; rhinitis. 
Abbreviations : ACQ, Asthma Control Questionnaire ; ACT, Asthma Control Test ; AR, Allergic rhinitis ; 
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Allergic rhinitis (AR) and asthma are highly prevalent conditions that generate a substantial health and economic 
burden (1-3). Despite the increased emphasis on the interactions between the upper and lower airways (3), there 
is limited evidence supporting an incremental impact of AR on asthma outcomes. Retrospective database studies 
indicated that the presence of AR is associated with a higher utilization of asthma-related healthcare resources, 
although controlled studies provided conflicting results regarding the benefits of treating AR  on asthma-related 
morbidity  (4-7).  Bousquet and co-workers demonstrated that both AR and asthma interfere with health-related 
quality of life (QOL) assessed through a generic instrument, the Short Form-36 Health Survey (8, 9). They found 
that AR was associated with impairment in social functioning and mental well-being, while subjects with both 
asthma and AR experienced more physical limitations than patients with AR alone (9). However, the relative 
contributions of asthma and AR to decreased QOL could not be delineated because of the limited number of 
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subjects with asthma without AR. Surveys of large samples of adult patients with asthma seen by general 
practitioners documented that the presence of (allergic) rhinitis was associated with a lower level of asthma 
control but asthma-related QOL was not investigated (10, 11). Only one recent study of patients with severe 
asthma documented an inverse correlation between the severity of rhinitis and the level of asthma-related quality 
of life assessed through the Asthma Quality of Life Questionnaire (6). 
The objective of this observational study was to assess the impact of concomitant rhinitis on asthma control and 
asthma-related QOL in a large population of patients with asthma. 
METHODS 
Study design 
This cross-sectional survey was conducted among patients with asthma identified by general practitioners and 
chest physicians randomly selected throughout Belgium and Luxemburg. Patients aged between 12 and 45 who 
had been treated for asthma for at least 1 year were eligible for inclusion in the study. The patients were enrolled 
during two 4-month periods (i.e. from March to June 2007 and from September to December 2007) to take into 
account seasonal variations in allergens. Participating physicians were asked to include up to 10 consecutive 
patients with asthma for general practitioners and up to 16 patients for chest physicians. 
Physicians and patients completed a questionnaire aimed at collecting information on demographic features (i.e. 
age, gender, and smoking habits) and outcomes related to asthma and rhinitis. A formal diagnosis of allergy was 
not an a priori inclusion criterion, although the questionnaire enquired whether sensitization to inhalant allergens 
(i.e. house dust mites, pets, molds, and tree, grass, or weed pollen) had been ascertained using either skin prick 
tests or measurement of specific IgE antibodies. The patient questionnaire was strictly anonymous and was 
completed during the clinical visit. The study protocol was approved by a central ethics committee (Universitair 
Ziekenhuis Antwerpen, Belgium), and the participants were requested to sign a statement of informed consent. 
Asthma outcomes 
The questionnaire collected information on the criteria used by the physicians for diagnosing asthma (i.e. clinical 
history alone, documentation of reversible airway obstruction on spirometry, or measurement of nonspecific 
airway hyperresponsiveness to pharmacological agents). The level of asthma control was assessed using the 6-
item Asthma Control Questionnaire (ACQ) in which the final item on airway obstruction is omitted (12, 13). 
Responses to each item are rated on a 6-point scale, and the global score is the mean of the responses ranging 
from 0 (totally controlled) to 6 (severely uncontrolled). When the ACQ is used to identify patients whose asthma 
is inadequately controlled, the optimal cutoff score is 1.50 (positive predictive value = 0.88) (13). 
Asthma-related QOL was assessed using the Mini Asthma Quality of Life Questionnaire (mAQLQ) (14). This 
15-item self-administered questionnaire has been designed to evaluate asthma-specific QOL by addressing four 
domains: (1) symptoms (5 items); (2) limitations in daily activities (4 items); (3) emotional function (3 items); 
and (4) exposure to environmental stimuli (3 items). The degree of impairment during the preceding 2 weeks is 
scored on a 7-point scale ranging from 1 (severe impairment) to 7 (no impairment) for each item. The answers 
are summarized into four domain scores and a mean global score. 
Rhinitis outcomes 
The clinical diagnosis of current rhinitis was based on a patient's positive answer to the question 'In the last 12 
months, have you had a runny or stuffy nose or episodes of sneezing when you did not have a cold or the flu?' 
(15). AR was defined by the presence of rhinitis symptoms associated with a declared sensitization to at least one 
aeroallergen. Patients were categorized as having nonallergic rhinitis (NAR) when they reported rhinitis 
symptoms in the absence of documented sensitization to common allergens. 
According to the Allergic Rhinitis and its Impact on Asthma (ARIA) recommendations (3), rhinitis was 
categorized into intermittent (symptoms < 4 days per week or for < 4 weeks) or persistent (symptoms > 4 days 
per week and for > 4 weeks) and further characterized according to severity as mild or moderate/severe (i.e. 
symptom rated as troublesome). 
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Data analysis 
Data are presented as mean ± SD for continuous variables and percentages for categorical variables. 
Comparisons between proportions and means were made using the chisquared test and Student's t-test, 
respectively. The factor that affected the primary outcomes (i.e. the dependent variables) of the study was 
explored through multivariate logistic regression analysis for the level of asthma control (i.e. ACQ score > 1.50 
vs ≤1.50) and multivariate linear regression analysis for asthma-related QOL (mAQLQ score). The 
characteristics of rhinitis symptoms and sociodemographic features (i.e. age, gender, and smoking status) were 
incorporated into these regressions as the independent variables. The effect of rhinitis on the primary outcomes 
was tested using two separate models. The first model used the presence of AR, NAR, or 'no-rhinitis' as 
independent variables, while the second model incorporated both the duration of rhinitis (i.e. persistent vs 
intermittent) and the severity of the symptoms (i.e. mild vs moderate/severe). 
The analysis was performed using the STATA 10.0 statistical software (StataCorp College Station, TX, USA). All 
tests were 2-tailed. A P-value <0.05 was considered significant. 
 
Table 1  Demographic and clinical features of the patients 
 All patients  
(n = 1173) n (%) 
Allergic rhinitis 
(n = 867) n (%) 
Nonallergic rhinitis 
(n = 160) n (%) 
No rhinitis 
(n = 146) n (%) 
P-value* 
Gender (female) 573 (49.3) 427 (49.7) 79 (49.7) 67 (46.5) 0.781 
Age† 29.9 ± 9.9 29.3 ± 9.8 31.7 ± 9.2 31.9 ± 10.1 <0.001 
Enrollment by general practitioner 665 (59.3) 486 (59.4) 109 (68.6) 70 (48.6) 0.002 
Smoking habits      
Nonsmokers 796 (68.6) 609 (71.1) 84 (52.8) 103 (71.5) <0.001 
Current smokers 224 (19.3) 155 (18.1) 47 (29.6) 22 (15.3)  
Ex-smokers 140 (12.1) 93 (10.9) 28 (17.6) 19 (13.2)  
Objective diagnosis of asthma‡ 912 (77.8) 689 (79.5) 103 (64.4) 120 (89.2) <0.001 
Asthma treatment      
Short-acting bronchodilator 799 (68.1) 594 (68.5) 111 (69.4) 94 (64.4) 0.572 
Inhaled corticosteroid 950 (81.0) 709 (81.8) 114 (71.3) 127 (87.0) 0.001 
Daily dose of corticosteroid§      
Low dose 224 (27.6) 165 (26.8) 32 (33.3) 27 (27.0) NS 
Medium dose 324 (39.9) 247 (40.1) 33 (34.4) 44 (44.0)  
High dose 264 (32.5) 204 (33.1) 31 (32.3) 29 (29.0)  
Long-acting beta2-agonist 317 (27.0) 233 (26.9) 37 (23.1) 47 (32.2) 0.200 
Leukotriene antagonist 459 (39.1) 352 (40.6) 58 (36.3) 49 (33.6) 0.197 
Oral corticosteroid 49 (4.2) 42 (4.8) 2 (1.3) 5 (3.4) 0.100 
Current conjunctivitis 839 (72.1) 723 (83.6) 105 (65.6) 11 (7.9) <0.001 
The results are presented as percentage of available data unless otherwise specified. NS, not statistically significant. 
*Comparing patients with allergic rhinitis, nonallergic rhinitis, and no rhinitis. 
†Mean ± SD. 
‡Objective diagnosis of asthma = documentation of variable airway obstruction through spirometry or assessment of nonspecific bronchia 
hyperresponsiveness to pharmacological agents. 
§Daily dose of inhaled corticosteroid expressed as beclomethasone dipropionate equivalent; low dose = less than 500 µg per day; medium 
dose = more than 500 µg but less than 1000 µg per day; and high dose = 1000 µg or more per day. 
 
RESULTS 
Demographic and clinical characteristics of the patients 
A total of 1173 eligible patients with asthma were recruited by 100 GPs and 46 chest physicians. Of the 1628 
initially recruited patients, 455 (27.9%) were excluded from analysis because they did not fulfill the inclusion 
criteria, i.e. age < 12 or > 45 years (n = 410), lack of information on asthma diagnosis (n = 33) or rhinitis 
diagnosis (n = 12). 
The demographic and clinical features of the patients are summarized in Table 1. The mean (±SD) age was 29.9 
± 9.9; 49.3% were women, and 19.3% were current smokers. The diagnosis of asthma was based on lung 
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function tests in 912 of 1173 (77.8%) subjects. A high proportion of patients with asthma (81.0%) were treated 
with an inhaled corticosteroid alone or associated with either a long-acting beta2-agonist (n = 403, 34.4%), a 
leukotriene receptor antagonist (n = 69, 5.9%), or both drugs (n = 330, 28.1%). Seven hundred and ninety-nine 
patients (68.1%) used an inhaled short-acting bronchodilator, which was the only anti-asthma medication for 
7.6% of the population. 
Symptoms of current rhinitis (i.e. within the past 12 months) were reported by 1027 of the 1173 (87.6%) 
patients. Sensitization to at least one inhalant allergen had been documented by either skin prick tests or specific 
IgE measurements in 79.9% of the patients, including 867 patients (i.e. 73.9% of the whole population) who 
experienced rhinitis symptoms and who were accordingly considered as having AR. One hundred and sixty 
(13.6%) participants experienced current symptoms of rhinitis but were categorized as having NAR in the 
absence of declared sensitization to inhalant allergens, while 146 (12.4%) participants did not report rhinitis 
symptoms. AR was associated with sensitization to house dust mites in 79.2% of the patients, tree pollen in 
40.8%, grass pollen in 41.9%, weed pollen in 44.4%, pets in 41.9%, and molds in 16.8%. The prevalence of AR 
was similar among patients recruited by general practitioners (486 of 665, 73.1%) and chest physicians (332 of 
456, 72.8%), although IgE sensitization to at least one common allergen was slightly more frequently reported   
among patients enrolled by chest physicians (82.2%) than in those recruited by general practitioner (77.0%, P = 
0.034). Patients diagnosed as having AR were slightly younger than those with NAR and those without rhinitis. 
More patients were current or ex-smokers in the NAR group (47.2%) than in the AR group (29.0%) and in those 
without rhinitis (28.5%). Patients with AR had more often a diagnosis of asthma documented by lung function 
tests (79.5%) than those with NAR (64.4%), but less often than those without rhinitis (89.2%). They were more 
often treated with an inhaled corticosteroid (81.8%) than patients with NAR (71.3%), although the distribution of 
daily dosage did not differ between the groups. Symptoms of conjunctivitis were more prevalent in patients with 
AR (83.6%) than in those with NAR (65.6%) and those without rhinitis (7.9%). 
The characteristics of rhinitis symptoms are presented in Table 2. The nasal symptoms were characterized as 
persistent by 49.1% and moderate/severe by 75.4% of the participants with rhinitis symptoms. Rhinitis was 
qualified as mild intermittent in 20.5% of these patients, mild persistent in 4.0%, moderate/severe intermittent in 
30.3%, and moderate/ severe persistent in 45.2%. Rhinitis was more often persistent and moderate/severe in 
patients with AR (50.9% and 77.3%, respectively) than in those with NAR. Noticeably, a high proportion of the 
patients (68.1%) with symptoms of rhinitis during the past 12 months experienced nasal symptoms at the time of 
the survey. Treatment of AR included an oral H1-antihistamine in 62.3% of the patients, nasal corticosteroids in 
58.8%, or a combination of these two medications in 39.6%. Patients with NAR took less often these  
medications (39.4%, 41.2%, and 22.5, respectively; P < 0.001). 
Table 2 Characteristics of rhinitis symptoms 
 All patients with rhinitis 
symptoms (n = 1027) n (%) 
Allergic rhinitis  
(n = 867) n (%) 
Nonallergic rhinitis  
(n = 160) n (%) 
P-value* 
Duration of rhinitis     
Intermittent 490 (50.9) 409 (49.1) 81 (52.8) <0.001 
Persistent 472 (49.1) 424 (50.9) 48 (37.2)  
Severity of rhinitis     
Mild 237 (24.6) 190 (22.7) 47 (36.4) <0.001 
Moderate/severe 727 (75.4) 645 (77.3) 82 (63.6)  
ARIA classes of rhinitis     
Mild intermittent 197 (20.5) 154 (18.5) 43 (33.3) <0.001 
Mild persistent 38 (4.0) 34 (4.1) 4 (3.1)  
Severe intermittent 291 (30.3) 253 (30.5) 38 (29.5)  
Severe persistent 434 (45.2) 390 (46.9) 44 (34.1)  
Rhinitis treatment     
Oral H1-antihistamine 603 (58.7) 540 (62.3) 63 (39.4) <0.001 
NCS 576 (56.1) 510 (58.8) 66 (41.2) <0.001 
Oral H1-antihistamine plus NCS 379 (36.9) 343 (39.6) 36 (22.5) <0.001 
Nasal decongestant 177 (17.2) 157 (18.1) 20 (12.5) <0.001 
No medication 132 (12.7) 88 (10.1) 44 (27.5) <0.001 
The results are presented as percentage of available data. 
ARIA, Allergic Rhinitis and its Impact on Asthma; NCS, nasal corticosteroid. 
*Comparing patients with allergic rhinitis to those with nonallergic rhinitis 
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Impact of AR on asthma control 
In the whole population, the mean ACQ score was 1.54 ± 1.07, and asthma was considered as being well 
controlled (i.e. ACQ equal to or less than 0.75) in only 27.8% of the patients. The mean ACQ score (Table 3) 
was higher in patient with AR (1.58 ± 1.05) and NAR (1.66 ± 0.09) than in those without rhinitis (1.13 ± 1.09, P 
< 0.001). The presence of co-morbid AR resulted in a significantly higher risk of uncontrolled asthma (i.e. ACQ 
score > 1.5) with an OR (95% confidence interval [CI]) of 1.96 (1.32-2.94). This effect was also observed for 
NAR (OR: 2.01 [1.22-3.32]). 
Both the severity and duration of rhinitis symptoms appeared to be important determinants of asthma control 
(Table 3). The odds of having uncontrolled asthma was higher (2.61 [1.90-3.59], P < 0.001) in patients with 
moderate/severe symptoms when compared to those who experienced mild symptoms. The risk of having 
uncontrolled asthma was significantly higher when the symptoms were persistent rather than intermittent (OR: 
1.97 [1.52-2.55], P < 0.001). 
The multivariate logistic regression analysis (Table 4) showed that the risk of uncontrolled asthma was increased 
by the presence of AR (adjusted OR: 2.00 [1.35-2.97]), NAR (OR: 1.77 [1.09-2.89]), and current smoking (OR: 
2.49 [1.82-3.42]). When the duration and severity of rhinitis were introduced in the regression analysis, having 
persistent (OR: 1.54 [1.16-2.05], P = 0.003) and moderate/severe symptoms (OR: 2.33 [1.64-3.30], P < 0.001), 
as well as being a women (OR: 1.39 [1.06-1.82], P = 0.016) or a current smoker (OR: 2.19 [1.54-3.12], P < 
0.001), was positively associated with uncontrolled asthma. 
 
Table 3 Impact of rhinitis on asthma contro 
 ACQ score* P-value Uncontrolled asthma 
(ACQ score >1.5)n (%) 
Crude ORs (95% CI) 
for uncontrolled asthma 
P-value 
Presence of rhinitis      
No rhinitis (n = 146) 1.13 ± 1.09 <0.001 43 (29.5) 1 0.002 
Allergic rhinitis (n = 867) 1.58 ± 1.05  390 (45.0) 1.96 (1.32-2.94)  
Nonallergic rhinitis (n = 160) 1.66 ± 1.09  73 (45.6) 2.01 (1.22-3.32)  
Severity of rhinitis      
Mild (n = 251) 1.24 ± 0.96 <0.001 71 (28.3) 1 <0.001 
Moderate/severe (n = 730) 1.71 ± 1.06  369 (50.6) 2.61 (1.90-3.59)  
Duration of rhinitis      
Intermittent (n = 506) 1.42 ± 0.94 <0.001 186 (36.8) 1 <0.001 
Persistent (n = 473) 1.77 ± 1.12  254 (53.7) 1.97 (1.52-2.55)  
ACQ, Asthma Control Questionnaire.  
*Mean ± SD. 
Impact of AR on asthma-related QOL 
Patients with AR and NAR reported significantly lower overall and individual domain mAQLQ scores (i.e. 
worse QOL) when compared to those who did not report rhinitis symptoms (Table 5). The mean (95%CI) 
difference between patients with AR and those without rhinitis was 0.67 (0.42-0.92) for the overall score, 0.63 
(0.36-0.90) for symptoms, 0.48 (0.27-0.69) for activities, 0.65 (0.34-0.96) for emotions, and 0.94 (0.72-1.16) for 
environmental stimuli. Comparing patients with NAR to those without rhinitis, the mean differences were 0.65 
(0.32-0.97) for the overall score, 0.70 (0.36-1.05) for symptoms, 0.57 (0.29-0.84) for activities, 0.58 (0.18-0.97) 
for emotions, and 0.94 (0.72-1.16) for environmental stimuli. Overall and individual mAQLQ scores were 
significantly lower (i.e. QOL was worse) in patients with moderate/severe compared to mild rhinitis, as well as 
in those with persistent compared to intermittent rhinitis (Table 5). 
In the multivariate linear regression analysis (Table 6), low mAQLQ scores were associated with higher ACQ 
scores (beta coefficient: -0.855, standard error [SE]: 0.019, P < 0.001), the presence of AR or NAR (beta 
coefficient: -0.293, SE: 0.063 and beta coefficient: -0.221, SE: 0.080, respectively, P < 0.001), and increasing 
age (beta coefficient: -0.005, SE: 0.002, P = 0.010). When incorporated in the model, the severity and the 
duration of rhinitis had both an adverse impact on QOL. Being a women resulted in a borderline negative effect 
in the tested models. 
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Table 4 Determinants of asthma contro 
Dependent variable Independent variables OR (95% CI)* P-value 
Model 1    
Uncontrolled Presence of rhinitis: 1 0.002 
asthma No rhinitis 2.00 (1.35-2.97)  
(ACQ score > 1.5) Allergic rhinitis: 1.77 (1.09-2.89)  
(n = 1150) Nonallergic rhinitis   
 Age (years) 1.01 (1.00-1.02) 0.138 
 Gender: 1 0.060 
 Male 1.26 (0.99-1.60)  
 Female   
 Smoking habits: 1 <0.001 
 Nonsmoker 1.02 (0.70-1.50)  
 Ex-smoker 2.49 (1.82-3.42)  
 Current smokers   
Model 2    
Uncontrolled Duration of rhinitis: 1 0.003 
asthma Intermittent 1.54 (1.16-2.05)  
(ACQ score > 1.5) Persistent   
(n = 942) Severity of rhinitis: 1 <0.001 
 Mild 2.33 (1.64-3.30)  
 Moderate/severe   
 Age (yrs) 1.01 (1.00-1.02) 0.151 
 Gender: 1 0.016 
 Male 1.39 (1.06-1.82)  
 Female   
 Smoking habits: 1 <0.001 
 Nonsmoker 0.98 (0.64-1.50)  
 Ex-smoker 2.19 (1.54-3.12)  
 Current smokers   
*Multivariate logistic regression analysis. 
 
Table 5 Impact of rhinitis on asthma-related quality of life 
  mAQLQ domains 
 Global mAQLQ score Symptoms Activities Emotions Environment P-value 
Presence of rhinitis       
Allergic rhinitis (n = 822) 5.01 ± 1.16 4.90 ± 1.26 5.39 ± 1.19 5.05 ± 1.45 4.61 ± 1.38 P < 0.001* 
Nonallergic rhinitis (n = 147) 5.03 ± 1.09 4.83 ± 1.22 5.30 ± 1.16 5.12 ± 1.41 4.72 ± 1.18  
No rhinitis (n = 138) 5.67 ± 1.06 5.54 ± 1.19 5.87 ± 1.04 5.70 ± 1.33† 5.55 ± 1.23  
Severity of rhinitis       
Mild (n = 251) 5.42 ± 1.02 5.26 ± 1.18 5.68 ± 1.01 5.51 ± 1.32 5.18 ± 1.22 P < 0.001‡ 
Moderate/severe (n = 730) 4.87 ± 1.14 4.77 ± 1.24 5.27 ± 1.21 4.90 ± 1.44 4.43 ± 1.33  
Duration of rhinitis       
Intermittent (n = 506) 5.23 ± 1.00 5.13 ± 1.09 5.56 ± 1.05 5.30 ± 1.30 4.85 ± 1.27 P < 0.001§ 
Persistent (n = 473) 4.77 ± 1.23 4.66 ± 1.34 5.18 ± 1.26 4.80 ± 1.51 4.37 ± 1.38  
Legend: Data are presented as mean ± SD; mAQLQ, Mini Asthma Quality of Life Questionnaire. 
*Comparing 'no rhinitis' with allergic rhinitis and nonallergic rhinitis (with the exception of emotional functioning) after Bonferroni 
correction. 
†P < 0.001 and P = 0.002 when compared with allergic rhinitis and nonallergic rhinitis, respectively. 
‡Comparing moderate/severe to mild rhinitis. 
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Table 6 Determinants of asthma-related quality of life 
Dependent variable Independent variables β (SE)* P-value 
Model 1    
Global ACQ score -0.855 (0.019) <0.001 
   mAQLQ Presence of rhinitis: 0 <0.001 
   score No rhinitis -0.293 (0.063)  
   (n = 1085) Allergic rhinitis: -0.221 (0.080)  
 Nonallergic rhinitis   
 Age (years) -0.005 (0.002) 0.010 
 Gender: 0 0.058 
 Male -0.077 (0.041)  
 Female   
 Smoking habits: 0 0.271 
 Nonsmoker -0.090 (0.065)  
 Ex-smoker -0.061 (0.054)  
 Current smokers   
Model 2    
Global ACQ score -0.843 (0.023) <0.001 
   mAQLQ Duration of rhinitis: 0 0.011 
   score Intermittent -0.125 (0.049)  
   (n = 890) Persistent   
 Severity of rhinitis: 0 0.039 
 Mild -0.118 (0.057)  
 Moderate/severe   
 Age (years) -0.006 (0.002) 0.013 
 Gender: 0 0.049 
 Male -0.090 (0.045)  
 Female   
 Smoking habits: 0 0.129 
 Nonsmoker -0.081 (0.060)  
 Ex-smoker -0.128 (0.073)  
 Current smokers   
ACQ, Asthma Control Questionnaire; mAQLQ, Mini Asthma Quality of Life Questionnaire. 
*Multivariate linear regression analysis. 
 
DISCUSSION 
This observational survey indicates that AR has an incremental adverse impact on asthma control and disease-
specific QOL of patients with asthma. These findings confirm recent reports showing a negative effect of AR on 
the level of asthma control using the ACQ in population-based studies of adult patients with asthma seen by 
general practitioners (10, 11). In addition, we found a detrimental effect of concomitant AR on asthma-related 
QOL, even after adjusting for the level of asthma control and sociodemographic characteristics of the population 
(i.e. age, gender, and smoking habits). A previous population-based study using a generic QOL questionnaire 
documented that subjects with both asthma and AR experienced more physical limitations than those suffering 
from AR alone (9). In that study, the effect of AR on QOL in patients with asthma could not be specifically 
characterized because of the low number of subjects with asthma without AR in the surveyed population. More 
recently, a clinic-based study evaluated the impact of rhinitis on QOL using the 'Rhinasthma' questionnaire; an 
instrument that has been designed to assess the QOL related both to the upper and lower airways (16). The 
logistic regression analysis showed that rhinitis symptoms affected QOL related to the upper airways and the 
'global summary score', while they had no effect on the level of QOL pertaining to the lower airways. The latter 
was predominantly influenced by the level of asthma control, as assessed by the Asthma Control Test. 
The clinical relevance of these findings, however, remains uncertain. Identifying an impact of concomitant AR 
on asthma control and asthma-related QOL may lead to assume that treatment of nasal disease would reduce the 
morbidity of asthma. A number of studies indicated that co-morbid AR is associated with a more frequent use of 
asthma-related medications and healthcare resources, and a higher cost-of-illness (4, 10). Epidemiological 
studies have suggested that treatment of AR is associated with a lower risk of emergency department visits and 
hospitalization for asthma (17-19), although these findings remain largely controversial (7). Juniper and cowork-
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ers defined a 'minimal important difference' of 0.5 as the smallest difference in AQLQ score that would justify a 
change in the patient's treatment in the absence of troublesome side-effects or excessive cost (20) In this study, 
most of the mean differences in mAQLQ scores attributable to the presence of AR and NAR exceeded this 
'minimal important difference'. However, the concept of 'minimal important difference' has been designed for 
interpreting changes in QOL over time in the same group of patients and may not be appropriate for comparing 
two populations at the same time point. 
Although assessment of AR was the primary aim of this study, the results revealed that rhinitis by itself had a 
substantial impact on asthma outcomes independent of the allergic status. These findings are consistent with 
earlier clinical data, suggesting that nasal symptoms are associated with more severe asthma in nonatopic 
patients (21). In addition, it has been reported that rhinitis is a stronger risk factor for asthma in the nonatopic 
compared with the atopic population (22). These data outline the need to enhance our understanding of the 
association between the upper and lower airways in nonallergic patients (23). 
The survey was conducted using validated questionnaires in a large population of patients with a physician-based 
diagnosis of asthma, among whom the diagnosis was ascertained by lung function tests in 77.8%. The subjects 
were enrolled over the pollen and mite seasons to overcome the possible seasonal differences in symptoms and 
reporting. Nevertheless, several potential limitations of this study should be considered. The sample of surveyed 
patients is unlikely to be representative of the general asthma population. Instead, the recruitment of patients 
with asthma through both general practitioners and chest physicians was intended to gather a sufficient number 
of patients with asthma with different levels of disease severity who did not experience rhinitis symptoms. The 
identification of AR was based on a symptom questionnaire and declared sensitization to allergens, which may 
have led to overestimation of the condition. The prevalence of AR among patients with asthma was similar to 
data found in the European Community Respiratory Health Survey (78%) (9). The pattern of severity and 
duration of rhinitis symptoms were also similar to the figures reported in a previous survey of the Belgian 
population (24) and surveys of patients recruited by general practitioners and chest physicians in other European 
countries (25, 26). An unknown proportion of rhinitis symptoms might have been misclassified as nonallergic, 
because the presence of IgE-mediated sensitization to common allergens was not assessed in all patients but was 
based on the physicians' report. Noticeably, a slightly higher proportion of patients enrolled by chest physicians 
(82.2%) had a documented sensitization to allergens when compared to those recruited by general practitioner 
(77.0%). Nevertheless, there is no indication that such a misclassification of AR as NAR could have affected the 
findings, because both conditions had an impact on asthma control and QOL. The study population included 
only patients aged above 12; assessing the impact of rhinitis in younger patients with asthma warrants further 
investigation using questionnaire instruments validated for children. 
Despite its inherent limitations, this study provides direct evidence supporting an additive impact of AR and 
NAR on the physical and emotional well-being of patients with asthma and confirms the negative effect of 
allergic rhinitis, but also nonallergic rhinitis, on asthma control. These findings further highlight the impact of 
rhinitis on asthma and underscore the need for incorporating the management of upper airways in a global 
therapeutic approach of asthma, as recommended in the ARIA guidelines (3). Prospective investigations are, 
however, required to determine whether appropriate treatment of rhinitis would improve asthma outcomes. 
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